PT - JOURNAL ARTICLE AU - GIOVANNI BATTISTA DI PIERRO AU - PIETRO GRANDE AU - LIVIO MORDASINI AU - HANSJÖRG DANUSER AU - AGOSTINO MATTEI TI - Safety and Efficacy of Robot-assisted Radical Prostatectomy in a Low-volume Center: A 6-year Single-surgeon Experience DP - 2016 Aug 01 TA - Anticancer Research PG - 4201--4207 VI - 36 IP - 8 4099 - http://ar.iiarjournals.org/content/36/8/4201.short 4100 - http://ar.iiarjournals.org/content/36/8/4201.full SO - Anticancer Res2016 Aug 01; 36 AB - Aim: To analyze safety and efficacy of robot-assisted radical prostatectomy (RARP) in a low-volume centre. Patients and Methods: From 2008 to 2015, 400 consecutive patients undergoing RARP were prospectively enrolled. Complications were classified according to the Modified Clavien System. Biochemical recurrence (BCR) was defined as two consecutive prostate-specific antigen (PSA) values ≥0.2 ng/ml. Functional outcomess were assessed using validated, self-administered questionnaires. Results: Median patient age was 64.5 years. Mean standard deviation (SD) preoperative PSA level was 11.3 (11.7) ng/ml. Median interquartile range (IQR) follow-up was 36 (12-48) months. Overall complication rate was 27.7% (minor complications rate 16.2%). Overall 1-, 3- and 6-year BCR-free survival rates were 85.7%, 77.5% and 53.9%, respectively; these rates were 94.1%, 86.2% and 70.1% in pT2 diseases. At follow-up, 98.4% of patients were fully continent (median (IQR) time to continence was 2 (1-3) months) and 68.2% were potent (median (IQR) time to potency of 3 (3-4) months). Conclusion: RARP appears to be a valuable option for treating clinically localised prostate cancer also in a low-volume institution.